Description: Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. It operates in two segments, which include Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their drug names. The Impax Specialty Pharma is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
Home Page: www.amneal.com
AMRX Technical Analysis
400 Crossing Boulevard
Bridgewater,
NJ
08807
United States
Phone:
908 947 3120
Officers
| Name | Title |
|---|---|
| Mr. Chirag K. Patel | Co-Founder, Co-CEO, Pres & Director |
| Mr. Chintu Patel R.Ph, R.Ph. | Co-Founder, Co-CEO & Director |
| Mr. Anastasios G. Konidaris | Exec. VP & CFO |
| Ms. Nikita Shah | Exec. VP and Chief HR & Strategic Planning Officer |
| Mr. Andrew S. Boyer | Exec. VP & Chief Commercial Officer of Generics |
| Mr. Anthony DiMeo | Sr. Director of Investor Relations |
| Mr. Jason B. Daly Esq. | Sr. VP, Chief Legal Officer & Corp. Sec. |
| Mr. Sanjiv Patel | Sr. VP of Operations |
| Dr. Nikunj Patel | Head of Ops & Exec. VP of Amneal Pharmaceuticals (India) Pvt Ltd |
| Mr. Sanjay Kumar Jain Ph.D. | Pres of India Operations |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 6.2972 |
|---|---|
| Trailing PE: | 220 |
| Price-to-Book MRQ: | 1.1865 |
| Price-to-Sales TTM: | 0.3221 |
| IPO Date: | 2009-01-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 7000 |